Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T-Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

被引:98
作者
Donia, Marco [1 ,2 ,3 ]
Andersen, Rikke [1 ,2 ]
Kjeldsen, Julie W. [1 ]
Fagone, Paolo [3 ]
Munir, Shamaila [1 ]
Nicoletti, Ferdinando [3 ]
Andersen, Mads Hald [1 ]
Straten, Per Thor [1 ]
Svane, Inge Marie [1 ,2 ]
机构
[1] Univ Copenhagen, Herlev Hosp, Ctr Canc Immune Therapy, Dept Hematol, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Univ Catania, Dept Biomed Sci, Catania, Italy
关键词
INFILTRATING LYMPHOCYTES; ANTIGEN EXPRESSION; CD4+T CELLS; THERAPY; RESPONSES; SAFETY; LINES; PROTEASOME; ANTI-PD-1; STANDARD;
D O I
10.1158/0008-5472.CAN-14-2956
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the absence of a local inflammatory response, expression of MHC class II molecules is restricted mainly to hematopoietic cells and thymus epithelium. However, certain tumors, such as melanoma, may acquire aberrant constitutive expression of MHC class II. In a set of primary melanoma cell populations and correspondingly expanded autologous tumor-infiltrating lymphocytes (TIL), we show how MHC class II expression on melanoma cells associates with strong MHC class II-restricted CD4(+) T-cell responses that are specific for tumors. Notably, we found that tumor-specific CD4(+) T-cell responses were dominated by TNF production. TNF reduced CD8(+) T-cell activation in IFN gamma-rich environments resembling a tumor site. Conversely, direct CD4(+) T-cell responses had no influence on either the proliferation or viability of melanoma cells. Taken together, our results illustrate a novel immune escape mechanism that can be activated by aberrant expression of MHC class II molecules, which by attracting tumor-specific CD4(+) T cells elicit a local inflammatory response dominated by TNF that, in turn, inhibits cytotoxic CD8(+) T-cell responses (C) 2015 AACR.
引用
收藏
页码:3747 / 3759
页数:13
相关论文
共 45 条
  • [1] Almeida J, 2009, BLOOD, V6, P246
  • [2] Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
    Altomonte, M
    Fonsatti, E
    Visintin, A
    Maio, M
    [J]. ONCOGENE, 2003, 22 (42) : 6564 - 6569
  • [3] Andersen MH, 1999, J IMMUNOL, V163, P3812
  • [4] Dissection of T-cell Antigen Specificity in Human Melanoma
    Andersen, Rikke Sick
    Thrue, Charlotte Albaek
    Junker, Niels
    Lyngaa, Rikke
    Donia, Marco
    Ellebaek, Eva
    Svane, Inge Marie
    Schumacher, Ton N.
    Straten, Per Thor
    Hadrup, Sine Reker
    [J]. CANCER RESEARCH, 2012, 72 (07) : 1642 - 1650
  • [5] Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients
    Anichini, Andrea
    Mortarini, Roberta
    Nonaka, Daisuke
    Molla, Alessandra
    Vegetti, Claudia
    Montaldi, Elisabetta
    Wang, Xinhui
    Ferrone, Soldano
    [J]. CANCER RESEARCH, 2006, 66 (12) : 6405 - 6411
  • [6] Baitsch L, 2011, J CLIN INVEST, V3, P23
  • [7] Class II transactivator (CIITA) isoform expression and activity in melanoma
    Baton, F
    Deruyffelaere, C
    Chapin, M
    Prod'homme, T
    Charron, D
    Al-Daccak, R
    Alcaide-Loridan, C
    [J]. MELANOMA RESEARCH, 2004, 14 (06) : 453 - 461
  • [8] HLA-DR ANTIGEN EXPRESSION IN PRIMARY MELANOMAS OF THE SKIN
    BROCKER, EB
    SUTER, L
    SORG, C
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1984, 82 (03) : 244 - 247
  • [9] IFN-α mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome
    Cangemi, G
    Morandi, B
    D'Agostino, A
    Peri, C
    Conte, R
    Damonte, G
    Ferlazzo, G
    Biassoni, R
    Melioli, G
    [J]. INTERNATIONAL IMMUNOLOGY, 2003, 15 (12) : 1415 - 1421
  • [10] 2011: the immune hallmarks of cancer
    Cavallo, Federica
    De Giovanni, Carla
    Nanni, Patrizia
    Forni, Guido
    Lollini, Pier-Luigi
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (03) : 319 - 326